tbuckley/cabot-search huggingface dataset:
NCCN News
Journal: Journal of the National Comprehensive Cancer Network (2014)

a highlight of the NCCN 20th Annual Conference will be a special roundtable titled, "20 Years of Improving Cancer Care Together."In recognition of NCCN's 20th Anniversary, this roundtable will be comprised of NCCN leadership-past and present-and other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years.Noteworthy historical NCCN accomplishments and events will be discussed, and the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.This special 20th Anniversary Roundtable will be filmed and endured on NCCN.org.For more information about the NCCN 20th Annual Conference, visit NCCN.org/AC2015.
Diagnosing Hydrocephalic Dementia
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Optimization of the first line treatment in classical Hodgkin's lymphoma
Authors: Pauline Brice
Journal: HemaSphere (2018)

Hopital Saint Louis, Paris, France This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Authors: Anthony Cmelak, Shuli Li, Shanthi Marur, Weiqiang Zhao, William H. Westra, Christine H. Chung, Maura L. Gillison, Jill Gilbert, Julie E. Bauman, Lynne I. Wagner, Robert L. Ferris, David R. Trevarthen, A. Dimitrios Colevas, Balkrishna N. Jahagirdar, Barbara Burtness
Journal: Journal of Clinical Oncology (2014)

LBA6006 Background: HPV+ patients (pts) in E2399 obtained a 2-yr 95% survival and 86% PFS after IC and 70Gy chemoradiation. We hypothesized reduced-dose IMRT (54Gy, 23% reduction) in HPV+ OPSCC pts could maintain high LR control and 85% 2-yr PFS in pts with cCR to IC. Methods: Pts with resectable stage III/IVa,b HPV+ OPSCC received IC q3 weeks x 3 with paclitaxel 90mg/m2 days (D) 1,8,15, cisplatin 75mg/m2 D1, and standard cetuximab (Cetux) weekly schedule. IC response determined IMRT dose independently at primary and involved nodes: IMRT 54Gy/27 if cCR vs. 69.3Gy/33 if <cCR. Cetux was continued during IMRT. Primary endpoint was 2-yr PFS. Results: 90 pts were enrolled (80 analyzable). Med FU is 23.3 months (mo). Tumor and Nodal stage: T4-10%, T3-17%, T2-50%, and T1-23%; N0,1-16%, N2a,b-54%, N2c-31%. Med age 57yrs. 46% never smoked and 84% not current smokers. IC and C-IMRT was well tolerated: 96% received all 3-cycles of IC. 71% had cCR. 62 pts (78%) received reduced-dose Cetux-IMRT. For all reduced IMRT pts, 23mo PFS is 84%, primary site LC 94%, nodal control 95%, and distant 92%. Post-treatment neck dissection was positive for tumor in 4/8 reduced dose IMRT pts compared to 1/3 pts treated with std dose. One late grade 3 toxicity occurred in 1 reduced-dose pt: hypomagnesemia at 30mo. Conclusions: IC + reduced-dose Cetux-IMRT produced high tumor control rates. Late toxicities were minimal. Low dose pts achieved 84% PFS at 23mo and 95% 2-yr survival. Pts with <10yrs smoking, T1-3 and N0-2b disease achieved 96% PFS. Further studies of reduced-dose IMRT in chemoresponsive HPV+ pts are warranted. Clinical trial information: NCT01084083. Variable (n) 23mo PFS (90% CI) 24mo OS (90% CI) All reduced-dose pts ( 62) 0.84 (0.74, 0.90) 0.95 (0.87, 0.98) T4A (7) 0.69 (0.29,0.89) 0.86 (0.45, 0.97) T1-T3(55) 0.86 (0.75, 0.92) 0.96 (0.88, 0.99) N2C (19) 0.77 (0.56, 0.89) 0.95 (0.76, 0.99) N0-N2b(43) 0.87 (0.75, 0.94) 0.95 (0.85, 0.98) Smoker > 10 pkyr (21) 0.71 (0.48, 0.85) 0.90 (0.71, 0.97) Smoker <= 10 pkyr (40) 0.92 (0.81, 0.97) 0.97 (0.87, 0.995) Smoker<=10 pkyr, <T4, <N2c (n=27) 0.96 (0.82, 0.99) 0.96 (0.82, 0.99) All standard-dose pts (15) 0.64 (0.39, 0.81) 0.87 (0.63, 0.96)
A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).
Authors: Philipp le Coutre, Kapil Bhalla, Francis Giles, Michele Baccarani, Gert J. Ossenkoppele, Andreas Hochhaus, Norbert Gattermann, Teresa Rafferty, Ariful Haque, Aaron Weitzman, Hagop Kantarjian
Journal: Blood (2006)
The Medical Colleges of the United States.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New AMA-RPS Chairperson Focuses on Implementing Reforms
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Question of Damaging Effect of Contrast Medium on Joints
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The real-world systemic sequential therapy of sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
Authors: Yoonseok Lee, Sung Won Chang, Min-jin Lee, Ji Hoon Kim, Soo Min Bang, Sehwa Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang
Journal: Journal of Hepatology (2020)
Book Review International Studies on the Relation Between the Private and Official Practice of Medicine with Special Reference to the Prevention of Disease Conducted for the Milbank Memorial Fund . By Sir Arthur Newsholme, K.C.B., M.D., F.R.C.P. Volume Three, England and Wales, Scotland, Ireland. Published by George Allen &amp; Unwin, Ltd., London; and Williams &amp; Wilkins Co., Baltimore. Price $5.00.
Journal: New England Journal of Medicine (1932)
Acute Pulmonary Toxicity of Particulate Matter Filter Extracts in Rats: Coherence with Epidemiologic Studies in Utah Valley Residents
Authors: Janice A. Dye, James R. Lehmann, John K. McGee, Darrell W. Winsett, Allen D. Ledbetter, Jeffrey I. Everitt, Andrew J. Ghio, Daniel L. Costa
Journal: Environmental Health Perspectives (2001)
Transient Myopia
Authors: Richard L. Sogg
Journal: JAMA (1972)

<h3>To the Editor.—</h3> I read with interest the LETTER of Weinstock (<b>217</b>:1245, 1971) on transient severe myopia. He and the readership in general might be interested to know of a case report of transient myopia associated with acute glaucoma and retinal edema.<sup>1</sup>In that case report, as is obvious from the title, more than a mere myopia resulted from the vaginal administration of sulfanilamide. Indeed, tensions as high as 40.2 mm Hg in the right eye and 43.4 mm Hg in the left eye, with closed angles, resulted. Maddalena discovered in his look through the literature that glaucoma had previously been reported by Jampolsky and Flom<sup>2</sup>following the use of aspirin in a case of myopia, and glaucoma following the ingestion of acetazolamide reported by Korol.<sup>3</sup>
Alkalosis Remains Post-Trauma Hazard
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The future of psychiatry. Council on Long Range Planning and Development
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Strong Woman
Authors: Tracey Gratch
Journal: Annals of Internal Medicine (2010)

Ad Libitum19 January 2010Strong WomanTracey GratchTracey GratchFrom Quincy, MA 02169.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-2-201001190-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail (for the mom at preschool drop-off)When I think I'm having a bad morning,coaxing kids out of the van, late, heading in,I see her across the parking lot, rail-thin;her face pale and gaunt, the hair—a warning.Early May—the Mother's Day Tea's Friday.How are you? Fine, she says, beneath her pain.I think, how brave. A smile—brief—she feigns.Kids run ahead, I want to ask, in some way,but can't. At night, I lie awake thinking—of risk factors, and predispositions.After I have prayed for her remission,I dream; I'm treading water, swimming, sinking.The next day—I nod ... Author, Article, and Disclosure InformationAffiliations: From Quincy, MA 02169.Current Author Address: Tracey Gratch, 141 Plymouth Avenue, Quincy, MA 02169. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 January 2010Volume 152, Issue 2Page: 92KeywordsMedical risk factorsSwimmingTeaWalking ePublished: 19 January 2010 Issue Published: 19 January 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Apple News
Authors: Natthida Khajornjiraphan, Nyein Aye Thu, Pierce Kah Hoe Chow, Julien Edeline, Marine Gilabert, Etienne Garin, Eveline Boucher, Jean-Luc Raoul, Masatoshi Kudo, Ronnie Tung-Ping Poon, Tom Tan-To Cheung, Philip Chong-Hei Kwok, Ann-Shing Lee, Tat-Wing Li, Kwok-Loon Loke, Stephen Lam Chan, Moon-Tong Cheung, Tak-Wing Lai, Chin-Cheung Cheung, Foon-Yiu Cheung, Ching-Kong Loo, Yiu-Kuen But, Shing-Jih Hsu, Simon Chun-Ho Yu, Thomas Yau, Linda C. Harlan, Helen M. Parsons, Charles L. Wiggins, Jennifer L. Stevens, Yehuda Z. Patt, Wei Teng, Ka-Wai Liu, Chen-Chun Lin, Wen-Juei Jeng, Wei-Ting Chen, I-Shyan Sheen, Chun-Yen Lin, Shi-Ming Lin
Journal: Liver Cancer (2015)
Goulstonian Lectures on the Chemical Pathology of Diphtheria, Compared with that of Anthrax, Infective Endocarditis, and Tetanus
Authors: S. Martin
Journal: BMJ (1892)

Kas the central zone was diseased and unable to assist, some of the iron had to remain in the still functional cells of the outer zone.If we take this view of the matter, then pernicious ansemia merely becomes a very severe form of anvemia generally, but no distinct disease.It becomes easy to understand how other forms may gradually become pernicious, and how per- nicious anaemia itself may recover by gradually passing into mailder forms.You will say, Surely the condition of the blood, the marked difference in the relation of the red corpuscles to the heemo- globin, and the changes in the corpuscles themselves are diagnostic marks indicating a fundamental divergence.But even this is not so irreconcileable a state as one is apt to imagine.I have at this present time a young girl under my care (Case I) in whom the red corpuscles are but 33 per cent., whilst the haemoglobin is as much as 28 per cent; yet there is no doubt that she is simply a chlorotic, with, it is true, symptoms of gastric ulcer.She shows no evidence of dangerous illness nor extreme feebleness; moreover, she is rapidly improving under Blaud's pills.The corpuscles may be most variable in size and shape in pernicious anemia, but they are by no means normal in these particulars in other anaemias; chlorosis is recognised to have a partiality for microcytes.It is only to be expected that the cells should most depart from their normal type in the severest form of the disease.Indeed, clinically, we are continually finding transition forms which more and more bridge the gap that still separates the per- nicious from simple anaemia.Often it is hard to tell the one from the other, and cases which begin with all the signs and symptoms of simple aneemia end fatally.Moreover, if we take a case of the most fatal and another of the mildest type of anaemia, these two certainly do not differ as much as a chronic tuberculous gland disease of the neck does from an acute miliary tuberculosis.[The lecturer concluded by discussing the relative influence of the blood, the capillary endothelium, and the heart in pro- ducing the cedema so common in ansemia.]
La Tension artérielle en clinique.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor
Authors: K. D. Holen, C. P. Belani, G. Wilding, S. Ramalingam, J. L. Volkman, R. K. Ramanathan, C. J. Bowen, D. D. Williams, M. M. Dar, P. T. C. Ho
Journal: Journal of Clinical Oncology (2005)

2010 Background: The mitotic kinesin KSP, plays an exclusive and essential role in assembly and function of the mitotic spindle. It is expressed in proliferating tumor cells, but is not expressed in terminally differentiated neurons. Targeting KSP may lead to the development of novel anti-mitotic drugs that lack neurotoxicity associated with anti-tubulin agents. SB-743921, the second KSP inhibitor to be evaluated in clinical trials, is a potent and selective inhibitor of KSP with a Ki of 100 pM and > 40,000-fold selectivity versus other kinesins. In pre-clinical studies, SB-743921 caused mitotic arrest and potent inhibition of tumor cell proliferation. SB-743921 was active in a broad range of human tumor xenografts. In some models, doses well below the maximum tolerated dose (MTD) of SB-743921 produced tumor regressions and cures. Methods: We initiated a phase I study to determine the MTD, tolerability, and PK profile of SB-743921 administered, IV over 60-minutes every 21 (Q 21) days (d). Interim Results: Eleven patients (pts) (M/F 6/5), median age 62 yrs (range 32- 73), with solid tumors were treated at doses of 2 - 8 mg/m2. Common tumor types included NSCLC (n=2), HCC (n=2), and CRC (n=2). Prolonged (≥5 d) Grade (Gr) 4 neutropenia was observed in 1 pt at 8 mg/m2 leading to an expanded cohort of 6 pts. Three further pts experienced a DLT in this cohort: prolonged Gr 4 neutropenia (n=2), Gr 3 elevated ALT/AST (n=1), and Gr 3 elevated bilirubin (n=1). The most common toxicities (all Gr 1) observed during this study included headaches (n=3), chills (n=3), nausea (n=3), myalgias (n=2), and injection site reactions (n=2). Gr 3 toxicities included neutropenia (n=1), acute abdominal pain (n=1), ileus (n=1), and fatigue (n=1). Median PK values in cycle 1 at 8 mg/m2 were as follows: Cmax 803.6 ng/ml, AUC0-∞ 10350.7 ng.hr/ml, and t½ 30.3 hr. Increases in AUC0-∞ and Cmax were dose-related. Conclusion: This is the first study of SB-743921 in humans. The MTD was exceeded at 8 mg/m2 Q 21 days due to prolonged neutropenia and hepatic lab abnormalities. Further dose exploration will continue at 6 mg/m2 to determine a MTD. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline Amgen, GlaxoSmithKline, Kosan, Pfizer, Roche, sanofi-aventis
SOME PATHOLOGIC RELATIONS OF LUSCHKA'S TONSIL.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal